Offering enhanced deep learning technology, the updated NeuroQuant 5.0 software reportedly bolsters segmentation capabilities for amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the updated NeuroQuant® 5.0 software, which offers enhanced magnetic resonance imaging (MRI)-based artificial intelligence (AI) capabilities for assessing patients being treated for Alzheimer’s disease and other neurological conditions.
NeuroQuant 5.0 features advanced segmentation and quantification for amyloid-related imaging abnormalities (ARIA) detected on brain MRI scans of patients being treated with anti-amyloid therapies for Alzheimer’s disease, according to Cortechs.ai, the manufacturer of the software.
The newly FDA-cleared NeuroQuant 5.0 software reportedly features advanced segmentation and quantification for amyloid-related imaging abnormalities (ARIA) for patients with Alzheimer’s disease as well as integration of of susceptibility-sensitive MRI sequences that enhance detection of smaller brain lesions, according to Cortechs.ai, the manufacturer of the software. (Image courtesy of Cortechs.ai.)
The company adds that the deep learning capabilities within NeuroQuant 5.0 facilitate improved visualization of lesions associated with traumatic brain injury (TBI), ARIA-E, ARIA-H and cerebral amyloid angiopathy. Another benefit of the NeuroQuant 5.0 software involves the integration of susceptibility-sensitive MRI sequences that enhance detection of smaller brain lesions, according to Cortechs.ai.
"With this release, we are transforming the way radiologists and neurologists approach neurological evaluations, helping to ensure more accurate and timely diagnoses for patients,” noted Kyle Frye, the chief executive officer at Cortechs.ai.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.